FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2001591858> ?p ?o ?g. }

• W2001591858 endingPage "4021" @default.
• W2001591858 startingPage "4014" @default.
• W2001591858 abstract "Control of gene expression by small molecule compounds is a novel therapeutic strategy for cancer and usually it requires the presence of specific molecular recognition. The development of the compounds preferentially binding to the specific DNA sequence is one of the potential but very difficult approaches in this strategy. We designed and synthesized novel napthalimidobenzamide derivatives and analyzed their binding preferences to oligonucleotides by EtBr-displacement assay with DNA sequences, being essential fragments of the genes. To test whether these compounds modify the expression of specific genes, we analyzed the effect on the gene expression in AZ521 cells by differential display analysis using the compounds showing different characteristics in the recognition of specific DNA sequence. Among them, DB-51630, which showed approximately 350 times higher preferential binding to GC-repeats than to the AT and AA-repeating oligomers, caused the induction of a specific mRNA. The genetic sequence was identified to be the p300 gene by sequencing of the cloned cDNA. The p300 is a transcriptional co-activator protein that acts with other nuclear proteins in various cell differentiation and signal transduction pathways. This protein has intrinsic histone acetyltransferase activity and may act on chromatin directly to facilitate transcription. The increase of the amount of p300 mRNA increased after DB-51630 treatment by real time RT-PCR and Northern blot analysis. DB-51630 inhibited cell growth in various cancer cell lines at nanomolar range of concentrations, whereas p300 mRNA induction was observed at sub-nanomolar concentrations and the maximal induction occurred 8 h after DB-51630 treatment. In contrast, anti-cancer drugs such as doxorubicin, vincristine, cisplatin, etoposide, and actinomycin D did not increase p300 transcription. DB-51630 revealed potent anti-cancer activity against human solid tumor xenografts. Thus, we demonstrated the anti-cancer activity of DB-51630, which interacts with a specific DNA sequence, thereby inducing p300 gene expression and exhibited significant anti-cancer activity in human tumor xenografts. Furthermore, such compounds that bind to specific DNA sequences may not only control the expression of specific genes but also exert other mechanisms in the anti-cancer effect than those of classical DNA binding drugs." @default.
• W2001591858 created "2016-06-24" @default.
• W2001591858 creator A5002280001 @default.
• W2001591858 creator A5005250738 @default.
• W2001591858 creator A5006108186 @default.
• W2001591858 creator A5016795795 @default.
• W2001591858 creator A5021532833 @default.
• W2001591858 creator A5023857268 @default.
• W2001591858 creator A5045958547 @default.
• W2001591858 creator A5048656899 @default.
• W2001591858 creator A5066192865 @default.
• W2001591858 creator A5068435121 @default.
• W2001591858 creator A5087292580 @default.
• W2001591858 creator A5088614355 @default.
• W2001591858 date "2005-06-01" @default.
• W2001591858 modified "2023-10-11" @default.
• W2001591858 title "Napthalimidobenzamide DB-51630: a novel DNA binding agent inducing p300 gene expression and exerting a potent anti-cancer activity" @default.
• W2001591858 cites W1503659987 @default.
• W2001591858 cites W1884928119 @default.
• W2001591858 cites W1900657670 @default.
• W2001591858 cites W1920934030 @default.
• W2001591858 cites W1966063731 @default.
• W2001591858 cites W1974938878 @default.
• W2001591858 cites W1975232450 @default.
• W2001591858 cites W1977299280 @default.
• W2001591858 cites W1978368163 @default.
• W2001591858 cites W1979841601 @default.
• W2001591858 cites W1982990113 @default.
• W2001591858 cites W1984618677 @default.
• W2001591858 cites W1985063313 @default.
• W2001591858 cites W1985933273 @default.
• W2001591858 cites W2002705413 @default.
• W2001591858 cites W2004988279 @default.
• W2001591858 cites W2012804357 @default.
• W2001591858 cites W2012823408 @default.
• W2001591858 cites W2018434022 @default.
• W2001591858 cites W2019336815 @default.
• W2001591858 cites W2021983664 @default.
• W2001591858 cites W2029758511 @default.
• W2001591858 cites W2030571655 @default.
• W2001591858 cites W2038492783 @default.
• W2001591858 cites W2038780419 @default.
• W2001591858 cites W2048743150 @default.
• W2001591858 cites W2049986428 @default.
• W2001591858 cites W2055213294 @default.
• W2001591858 cites W2062281282 @default.
• W2001591858 cites W2063853405 @default.
• W2001591858 cites W2063856094 @default.
• W2001591858 cites W2066804477 @default.
• W2001591858 cites W2070005479 @default.
• W2001591858 cites W2070061120 @default.
• W2001591858 cites W2070840393 @default.
• W2001591858 cites W2072924157 @default.
• W2001591858 cites W2072994395 @default.
• W2001591858 cites W2079597875 @default.
• W2001591858 cites W2088499279 @default.
• W2001591858 cites W2089218510 @default.
• W2001591858 cites W2094494461 @default.
• W2001591858 cites W2114612733 @default.
• W2001591858 cites W2145942488 @default.
• W2001591858 cites W2149316882 @default.
• W2001591858 cites W2166907165 @default.
• W2001591858 cites W2217698889 @default.
• W2001591858 cites W2346751714 @default.
• W2001591858 doi "https://doi.org/10.1016/j.bmc.2005.03.053" @default.
• W2001591858 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15911314" @default.
• W2001591858 hasPublicationYear "2005" @default.
• W2001591858 type Work @default.
• W2001591858 sameAs 2001591858 @default.
• W2001591858 citedByCount "30" @default.
• W2001591858 countsByYear W20015918582013 @default.
• W2001591858 countsByYear W20015918582014 @default.
• W2001591858 countsByYear W20015918582015 @default.
• W2001591858 countsByYear W20015918582016 @default.
• W2001591858 countsByYear W20015918582018 @default.
• W2001591858 countsByYear W20015918582019 @default.
• W2001591858 countsByYear W20015918582020 @default.
• W2001591858 countsByYear W20015918582021 @default.
• W2001591858 countsByYear W20015918582022 @default.
• W2001591858 countsByYear W20015918582023 @default.
• W2001591858 crossrefType "journal-article" @default.
• W2001591858 hasAuthorship W2001591858A5002280001 @default.
• W2001591858 hasAuthorship W2001591858A5005250738 @default.
• W2001591858 hasAuthorship W2001591858A5006108186 @default.
• W2001591858 hasAuthorship W2001591858A5016795795 @default.
• W2001591858 hasAuthorship W2001591858A5021532833 @default.
• W2001591858 hasAuthorship W2001591858A5023857268 @default.
• W2001591858 hasAuthorship W2001591858A5045958547 @default.
• W2001591858 hasAuthorship W2001591858A5048656899 @default.
• W2001591858 hasAuthorship W2001591858A5066192865 @default.
• W2001591858 hasAuthorship W2001591858A5068435121 @default.
• W2001591858 hasAuthorship W2001591858A5087292580 @default.
• W2001591858 hasAuthorship W2001591858A5088614355 @default.
• W2001591858 hasConcept C101762097 @default.
• W2001591858 hasConcept C104317684 @default.
• W2001591858 hasConcept C105580179 @default.
• W2001591858 hasConcept C129312508 @default.
• W2001591858 hasConcept C134320426 @default.

• next